Anti-Mouse CD24 (Clone M1/69) – Dylight® 594

This DyLight® 594 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Functional grade preclinical antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This DyLight® 594 conjugate is stable when stored at 2-8°C. Do not freeze.

Red Laser (590 nm)

IHC^{29, 31},
IF^{29, 30},
IF Microscopy^29,
IP18

Anti-CD24 antibody (clone M1/69) activity is directed against mouse CD24, also known as Heat Stable Antigen (HSA) or Ly-52.

Mouse CD24 is a small 27 amino acid sialoglycoprotein that is anchored to plasma membranes via a glycosyl-phosphatidylinositol linker¹. CD24 is widely distributed and plays a role in many diverse functions including adaptive immunity, inflammation, autoimmunity, and cancer^1,2. CD24 modulates growth and differentiation signals to granulocytes and B cells, is required for homeostatic cell renewal, binds to P-selectin on activated endothelial cells, plays a role in cell adhesion³, lymphocyte proliferation for homeostatic purposes⁴, lymphocyte costimulation via CD28-independent pathways⁵ as well as a crucial role in cell selection and maturation during hematopoiesis.

CD24 tends to be expressed more abundantly in progenitor cells and metabolically active cells relative to terminally differentiated cells². For example, CD24 is expressed on B-cell progenitors and mature resting B cells, but not terminally differentiated plasma cells. Similarly, CD24 is abundantly expressed on immature T cells and activated T cells but weakly expressed on peripheral T cells. As such, CD24 is used as a marker for the differentiation of hematopoietic and neuronal cells as well as tumor stem cells.

In humans, CD24 is overexpressed in various malignancies and its downregulation reduces cell tumorgenicity⁶. When CD24 is expressed early during carcinogenesis and blocked with monoclonal antibodies or small interfering RNA, tumor growth in xenograft mouse models is reduced.

M1/69 was generated by fusing the spleen cells of a DA rat immunized with B10 mouse spleen cells enriched for T cells with cells from a nonsecreting mouse myeloma line (NSI)⁷.

CD24 is expressed on B cells, T cells, neutrophils, eosinophils, macrophages, neural cells, ganglion cells, keratinocytes, muscle cells, pancreas cells, lymphocytes, granulocytes, epithelial cells, thymocytes, monocytes, erythrocytes, dendritic cells and is overexpressed in many cancers. Expression varies during T and B cell differentiation. Peripheral T cells are mainly negative.

P-selectin, CD24

1. Kay R, Takei F, Humphries RK. J Immunol. 145:1952–1959. 1990.
2. Fang X, Zheng P, Tang J, et al. Cell Mol Immunol. 7(2):100-103. 2010.
3. Aigner S, Ruppert M, Hubbe M, et al. Int Immunol. 7:1557–1565. 1995.
4. Li O, Zheng P, Liu Y. J Exp Med. 200:1083–1089. 2004.
5. Hubbe M, Altevogt P. Eur J Immunol 24:731–737. 1994.
6. Sagiv E, Starr A, Rozovski U, et al. Cancer Res. 68(8):2803-2812. 2008.
7. Springer T, Galfrè G, Secher DS, et al. Eur J Immunol. 8(8):539-551. 1978.
8. Takei F, Secher DS, Milstein C, et al. Immunology. 42(3):371-378. 1981.
9. Gracz AD, Ramalingam S, Magness ST. Am J Physiol Gastrointest Liver Physiol. 298(5):G590-G600. 2010.
10. Shafer MER, Nguyen AHT, Tremblay M, et al. Stem Cell Reports. 8(4):1018-1031. 2017.
11. Shortman K, Wilson A, Egerton M, et al. Cell Immunol. 113(2):462-479. 1988.
12. Veillette A, Zúñiga-Pflücker JC, Bolen JB, et al. J Exp Med. 170(5):1671-1680. 1989.
13. Koni PA, Flavell RA. J Exp Med. 189(5):855-864. 1999.
14. Chappaz S, Flueck L, Farr AG, et al. Blood. 110(12):3862-3870. 2007.
15. Rucci F, Notarangelo LD, Fazeli A, et al. Proc Natl Acad Sci U S A. 107(7):3024-3029. 2010.
16. Teague TK, Tan C, Marino JH, et al. Int Immunol. 22(5):387-397. 2010.
17. Qiu Q, Ravens I, Seth S, et al. J Immunol. 184(4):1681-1689. 2010.
18. Young GR, Terry SN, Manganaro L, et al. J Virol. 92(1):e01507-17. 2017.
19. Gubin MM, Esaulova E, Ward JP, et al. Cell. 175(4):1014-1030.e19. 2018.
20. Evrard M, Kwok IWH, Chong SZ, et al. Immunity. 48(2):364-379.e8. 2018.
21. Schneppenheim J, Loock AC, Hüttl S, et al. J Immunol. 199(1):172-185. 2017.
22. Hoves S, Ooi CH, Wolter C, et al. J Exp Med. 215(3):859-876. 2018.
23. Lee JY, Kim J, Yi J, et al. Front Immunol. 9:437. 2018.
24. Fiege JK, Stone IA, Dumm RE, et al. PLoS Pathog. 15(9):e1008077. 2019.
25. Krovi SH, Kappler JW, Marrack P, et al. Proc Natl Acad Sci U S A. 116(44):22252-22261. 2019.
26. Wu W, Shi Y, Xia H, et al. Sci Rep. 7:44481. 2017.
27. Arkatkar T, Jacobs HM, Du SW, et al. Kidney Int. 94(4):728-740. 2018.
28. Chappel MS, Hough MR, Mittel A, et al. J Exp Med. 184(5):1639-1649. 1996.
29. Liu JQ, Carl JW Jr, Joshi PS, et al. J Immunol. 178(10):6227-6235. 2007.
30. Wagner G, Lindroos-Christensen J, Einwallner E, et al. Sci Rep. 7:40881. 2017.
31. Chen CY, Kimura H, Landek-Salgado MA, et al. Endocrinology. 150(1):492-499. 2009.